Targeting of NF-kappab signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 13, Issue 1, 2013, Pages 16-34

  Fuchs, Ota ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Apoptosis; IkB ; MEK MAPK; Multiple myeloma; NF B; PI3K akt mTOR

Indexed keywords

2 [4 (1 HYDROXYIMINO 5 INDANYL) 3 (4 PYRIDINYL) 1H PYRAZOL 1 YL] ETHANOL; 2 [4 (1 HYDROXYIMINO 5 INDANYL) 3 (4 PYRIDINYL) 1H PYRAZOL 1 YL]ETHANOL; B CELL ACTIVATING FACTOR; BORTEZOMIB; CARFILZOMIB; CD40 ANTIGEN; CYCLIN D; CYCLIN DEPENDENT KINASE 6; CYCLIN E; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEMETHYLASE; HISTONE METHYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LENALIDOMIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITHRAMYCIN; N [3 (5 CHLORO 1H PYRROLO [2, 3 B] PYRIDINE 3 CARBONYL) 2, 4 DIFLUOROPHENYL] PROPANESULFONAMIDE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; POMALIDOMIDE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN SERINE THREONINE KINASE; SALINOSPORAMIDE A; TELOMERASE; THALIDOMIDE; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR HOXA9; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VEMURAFENIB;

ARTICLE; AUTOPHAGY; CELL CYCLE REGULATION; CELL GROWTH; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOBLOTTING; MULTIPLE MYELOMA; ONCOGENE C MYC; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); TUMOR MICROENVIRONMENT;

ANIMALS; EPIGENOMICS; GENE EXPRESSION PROFILING; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84876730349     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871529X11313010003     Document Type: Article

References (221)

1. Schwarzenbach, H. Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, the lung-resistance protein LRP in multiple myeloma. Med. Oncol, 2002, 19, 87-104.
2. Kastritis, E.; Mitsiades, C.S.; Dimopoulos, M.A.; Richardson, PG. Management of relapsed and relapsed refractory myeloma. Hematol. Oncol. Clin. N. Am., 2007, 21, 1175-1215.
3. Damiano, J.S.; Cress, A.E.; Hazlehurst, L.A.; Shtil, A.A.; Dalton, W.S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 1999, 93, 1658-1667.
4. Hazlehurst, L.A.; Damiano, J.S.; Buyuksal, I; Pledger, W.U.; Dalton, WS. Adhesion to fibronectin via (31 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene, 2000, 19, 4319-4327.
5. Tu, Y.; Gardner, A.; Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res., 2000, 60, 6763-6770.
6. Hideshima, T.; Nakamura, N; Chauhan, D.; Anderson, K.C. Biologic sequelae of interleukin-6 induced PI3K/Akt signaling in multiple myeloma. Oncogene, 2001, 20, 5991-6000.
7. Mitsiades, C.S.; Mitsiades, N; Poulaki, V.; Schlossman, R.; Akiyama, M.; Chauhan, D.; Fanourakis, G.; Gu, X.; Bailey, C; Joseph, M.; Libermann, T.A.; Schlossman, R.; Munshi, N.C.; Hideshima, T.; Anderson, K.C. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene, 2002, 21, 5673-5683.
8. Hideshima, T.; Anderson, K.C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat. Rev. Cancer, 2002, 2, 927-937.
9. Younes H, Leleu X.; Hatjiharissi, E.; Moreau, A.S.; Hideshima, T.; Richardson, P.; Anderson, K.C; Ghobrial, I.M. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin. Cancer Res., 2007, 13, 3771-3775.
10. Ferrajoli, A.; Faderl, S.; Ravandi, F.; Estrov, Z. The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr. Cancer Drug Targets, 2006, 6, 671-679.
11. Sagawa, M.; Nakazato, T; Uchida, H; Ikeda, Y; Kizaki, M. Cantharidin induces apoptosis of human multiple myeloma cells via inhibition of the JAK/STAT pathway. Cancer Sci., 2008, 99, 1820-1826.
12. Hayashi, T.; Hideshima, T.; Nguyen, A.N.; Munoz, O.; Podar, K.; Hamasaki, M.; Ishitsuka, K.; Yasui, H.; Richardson, P.; Chakravarty, S.; Murphy, A.; Chauhan, D.; Higgins, L.S.; Anderson, K.C. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin. Cancer Res., 2004, 10, 7540-7546.
13. Urashima, M.; Ogata, A.; Chauhan, D.; Hatziyanni, M.; Vidriales, M.B.; Dedera, D.A.; Schlossman R.L.; Anderson, K.C. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood, 1996, 87, 1928-1938.
14. Tian, E.; Zhan, F.; Walker, R.; Rasmussen, E.; Ma, Y.; Barlogie, B.; Shaughnessy, J.D. Jr. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl. J. Med, 2003, 349, 2483-2494.
15. Pearse, R.N. Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling. Clin. Cancer Res., 2006, 12(20, Pt 2), 6274s-6278s.
16. Jundt, F.; Pröbsting, KS.; Anagnostopoulos, I.; Muehlinghaus, G.; Chatterjee, M.; Mathas, S.; Bargou, R.C.; Manz, R.; Stein, H.; Dörken, B. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood, 2004, 103, 3511-3515.
17. Nefedova, Y.; Cheng, P.; Alsina, M.; Dalton, W.S.; Gabrilovich, D.I. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood, 2004, 103, 3503-3510.
18. Freund, G.G.; Kulas, D.T.; Mooney, R.A. Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226. J. Immunol, 1993, 151, 1811-1820.
19. Mitsiades, C.S.; Mitsiades, N.S.; McMullan, C.J.; Poulaki, V.; Shringarpure, R.; Akiyama, M.; Hideshima, T.; Chauhan, D.; Joseph, M.; Libermann, T.A.; García-Echeverría, C; Pearson, M.A.; Hofmann, F.; Anderson, K.C.; Kung, A.L. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell, 2004, 5, 221-230.
20. Chen, H.; Gordon, M.S.; Campbell, R.A.; Li, M.; Wang, C.S.; Lee, H.J.; Sanchez, E.; Manyak, S.J.; Gui, D.; Shalitin, D.; Said, J.; Chang, Y.; Deuel, T.F.; Baritaki, S.; Bonavida, B.; Berenson, J.R. Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth. Blood, 2007, 110, 287-295.
21. Intini, D.; Agnelli, L.; Ciceri, G.; Ronchetti, D.; Fabris, S.; Nobili, L.; Lambertenghi-Deliliers, G.; Lombardi, L.; Neri, A. Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma. Hematol.Oncol, 2007, 25, 6-10.
22. Bezieau, S.; Devilder, M.C.; Avet-Loiseau, H.; Mellerin, M.P.; Puthier, D.; Pennarun, E.; Rapp, M.J., Harousseau, J.L.; Moisan, J.P.; Bataille, R High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum. Mutat, 2001, 18, 212-224.
23. Berenson, J.R.; Ma, H.M.; Vescio, R. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin.Oncol, 2001, 28, 626-633.
24. Feinman, R.; Siegel, D.S.; Berenson, J. Regulation of NF-κB in multiple myeloma: therapeutic implications. Clin. Adv. Hematol. Oncol, 2004, 2, 162-166.
25. Annunziata, CM.; Davis, R.E.; Demchenko, Y.; Bellamy, W.; Gabrea, A.; Zhan, F.; Lenz, G.; Hanamura, I.; Wright, G.; Xiao, W.; Dave, S.; Hurt, E.M.; Tan, B.; Zhao, H.; Stephens, O.; Santra, M.; Williams, D.R; Dang, L.; Barlogie, B.; Shaughnessy, J.D. Jr.; Kuehl, W.M.; Staudt, L.M. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell, 2007, 12, 115-130.
26. Keats, J.J.; Fonseca, R.; Chesi, M.; Schop, R.; Baker, A.; Chng, W.J.; Van Wier, S.; Tiedemann, R.; Shi, C.X.; Sebag, M.; Braggio, E.; Henry, T; Zhu, Y.X.; Fogle, H.; Price-Troska, T; Ahmann, G.; Mancini, C; Brents, L.A.; Kumar, S.; Greipp, P.; Dispenzieri, A.; Bryant, B.; Mulligan, G; Bruhn, L.; Barrett, M.; Valdez, R.; Trent, J.; Stewart, A.K.; Carpten, J.; Bergsagel, PL. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell, 2007, 12, 131-144.
27. Conticello, C; Giuffrida, R.; Adamo, L.; Anastasi, G.; Martinetti, D.; Salomone, E.; Colarossi, C; Amato, G.; Gorgone, A.; Romano, A.; Iannolo, G.; De Maria, R.; Giustolisi, R.; Gulisano, M.; Di Raimondo, F. NF-κB localization in multiple myeloma plasma cells and mesenchymal cells. Leuk. Res., 2011, 35, 52-60.
28. Hideshima, T; Chauhan, D.; Podar, K.; Schlossman, R.L.; Richardson, P.; Anderson, K.C. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin. Oncol, 2001, 28, 607-612.
29. Chiron, D.; Jego, G.; Pellat-Deuceunynck, C. Toll-like receptors: expression and involvement in multiple myeloma. Leuk.Res., 2010, 34, 1545-1550.
30. Podar, K.; Anderson, K.C. Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies. Cell Cycle, 2007, 6, 538-542.
31. Freeman, M.R.; Di Vizio, D.; Solomon, K.R. The rafts of the medusa: cholesterol targeting in cancer therapy. Oncogene, 2010, 29, 3745-3747.
32. Mollinedo, F.; de la Iglesia-Vicente, J.; Gajate, C; Estella-Hermoso de Mondoza, A.; Villa-Pulgarin, J.A.; Campanero, M.A.; Blanco-Prieto, M.J. Lipid raft-targeted therapy in multiple myeloma. Oncogene, 2010, 29, 3748-3757.
33. Bharti, A.C.; Shishodia, S.; Reuben, J.M.; Weber, D.; Alexanian, R.; Raj-Vadhan, S.; Estrov, Z.; Talpaz, M.; Aggarwal, B.B. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood, 2004, 103, 3175-3184.
34. Bhardwaj A, Sethi, G.; Vadhan-Raj, S.; Bueso-Ramos, C; Takada, Y; Gaur, U.; Nair, A.S.; Shishodia, S.; Aggarwal, B.B. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood, 2007, 109, 2293-2302.
35. Malara, N.; Focà, D.; Casadonte, F; Sesto, MF; Macrina, L.; Santoro, L.; Scaramuzzino, M.; Terracciano, R.; Savino, R Simultaneous inhibition of the constitutively activated nuclear factor kappaB and of the interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells. Cell Cycle, 2008, 7, 3235-3245.
36. Khong, T; Sharkey, J.; Spencer, A. The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica, 2008, 93, 860-869.
37. Pene, F; Claessens, Y.E.; Muller, O; Viguié, F.; Mayeux, P.; Dreyfus, F; Lacombe, C; Bouscary, D. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene, 2002, 21, 6587-6597.
38. Pei, X.Y; Dai, Y; Tenorio, S.; Lu, J.; Harada, H.; Dent, P.; Grant, S. MEK 1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism. Blood, 2007, 110, 2092-2101.
39. Gera, J.; Lichtenstein, A. The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma. Leuk. Lymphoma, 2011, 52, 1857-1866.
40. Maiso, P.; Liu, Y; Morgan, B.; Kareem Azab, A.; Ren, P.; Martin, B.M.; Zhang, Y; Liu, Y; Sacco, A.; Ngo, H.; Azab F.; Quang, P.; Rodig, S.J.; Lin, C.P.; Roccaro, A.M.; Rommel, C; Ghobrial, I.M. Defining the role of TORC 1/2 in multiple myeloma. Blood, 2011, 118, 6860-6870.
41. Steinbrunn, T; Stühmer, T; Sayehli, C; Chatterjee, M.; Einsele, H.; Bargou, R.C. Combined targeting of MEK/MAPK and PI3K/Akt signaling in multiple myeloma. Br. J. Haematol, 2012, 159, 430-440.
42. Yang, J.; He, J.; Wang, J.; Cao, Y; Ling, J.; Qian, J.; Lu, Y; Li, H.; Zheng, Y; Lan, Y; Hong, S.; Matthews, J.; Starbruck, M.W.; Navone, N.M.; Orlowski, R.Z.; Lin, J.; Kwak, L.W.; Yi, Q. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia, 2012, 26, 2114-2123.
43. Stengel, C; Cheung, C.W.; Quinn, J.; Yong, K.; Khwaja, A. Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signaling and is determined by translocation subtype. Leukemia, 2012, 26, 1761-1770.
44. Glassford, J.; Kassen, D.; Quinn, J.; Stengel, C; Kallinikou, K.; Khwaja, A.; Yong, K.L. Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations. Blood Cancer J., 2012, 2, e50.
45. Chapman, M.A.; Lawrence, M.S.; Keats, J.J.; Cibulskis, K.; Sougnez, C; Schinzel, A.C.; Harview, C.L.; Brunet, J.P; Ahmann, G.J.; Adli, M.; Anderson, K.C; Ardlie, K.G.; Auclair, D.; Baker, A.; Bergsagel, PL.; Bernstein, B.E.; Drier, Y; Fonseca, R.; Gabriel, S.B.; Hofmeister, C.C.; Jagannath, S.; Jakubowiak, A.J.; Krishnan, A.; Levy, J.; Liefeld, T; Lonial, S.; Mahan, S.; Mfuko, B.; Monti, S.; Perkins, L.M.; Onofrio, R.; Pugh, T.J.; Rajkumar, S.V.; Ramos, A.H.; Siegel, D.S; Sivachenko, A.; Stewart, A.K.; Trudel, S.; Vij, R.; Voet, D.; Winckler, W.; Zimmerman, T; Carpten, J.; Trent, J.; Hahn, W.C.; Garraway, L.A.; Meyerson, M.; Lander, E.S.; Getz, G.; Golub, T.R. Initial genome sequencing and analysis of multiple myeloma. Nature, 2011, 471, 467-472.
46. Hayden, MS.; Ghosh S. Signaling to NF-κB. Genes Dev, 2004, 15, 2195-2224.
47. Gilmore, TD. Introduction to NF-kappa B: players, pathways, perspectives. Oncogene, 2006, 25, 6680-6684.
48. Ghosh, S.; Karin, M. Missing pieces in the NF-κB puzzle. Cell, 2002, 109(suppl.), S81-S96.
49. Hayden, MS.; Ghosh, S. Shared principles in NF-kappaB signaling. Cell, 2008, 132, 344-362.
50. Turco, MC; Romano, MF; Petrella, A.; Bisogni, R.; Tassone, P.; Venuta, S. NF-kappaB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia, 2004, 18, 11-17.
51. Li, Z.W.; Chen, H.; Campbell, R.A.; Bonavida, B.; Berenson, J.R. NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr. Opin. Hematol, 2008, 15, 391-399.
52. Sha, W.C.; Liou, H.C.; Tuomanen, E.I.; Baltimore, D. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell, 1995, 80, 321-330.
53. Köntgen, F.; Grumont, R.J.; Strasser, A.; Metcalf, D.; Li, R.; Tarlinton, D.; Gerondakis, S. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev., 1995, 9, 1965-1977.
54. Franzoso, G.; Carlson, L.; Poljak, L.; Shores, EW.; Epstein, S.; Leonardi, A.; Grinberg, A.; Tran, T.; Scharton-Kersten, T.; Anver, M.; Love, P.; Brown, K.; Siebenlist, U. Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J. Exp. Med., 1998, 187, 147-159.
55. Yamaoka, S.; Courtois, G.; Bessia, C; Whiteside, ST.; Weil, R.; Agou, F.; Kirk, H.E.; Kay, R.J.; Israël, A. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell, 1998, 93, 1231-1240.
56. Rothwarf, D.M.; Zandi, E.; Natoli, G.; Karin, M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature, 1998, 395, 297-300.
57. Mercurio, F.; Murray B.W.; Shevchenko, A.; Bennett, B.L.; Young, D.B.; Li, J.W.; Pascual, G.; Motiwala, A.; Zhu, H.; Mann, M.; Manning, A.M. IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex. Mol. Cell. Biol, 1999, 19. 1526-1538.
58. Maniatis, T. A ubiquitin ligase complex essential for the NF-κB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev., 1999, 13, 505-510.
59. Karin, M.; Ben-Neriah, Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol, 2000, 18, 621-663.
60. Werner, S.L.; Barken, D.; Hoffmann, A. Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science, 2005, 309, 1857-1861.
61. Park, J.M.; Greten, F.R.; Wong, A.; Westrick, R.J.; Arthur, J.S.; Otsu, K.; Hoffmann, A.; Montminy, M.; Karin, M. Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis--CREB and NF-kappaB as key regulators. Immunity, 2005, 23, 319-329.
62. Covert, M.W.; Leung, T.H.; Gaston, J.E.; Baltimore, D. Achieving stability of lipopolysaccharide-induced NF-kappaB activation. Science, 2005, 309, 1854-1857.
63. Hoffmann, A.; Natoli, G.; Ghosh, G. Transcriptional regulation via the NF-kappaB signaling module. Oncogene, 2006, 25, 6706-6716.
64. Senftleben, U.; Cao, Y; Xiao, G.; Greten, F.R.; Krähn G, Bonizzi, G.; Chen, Y; Hu, Y; Fong, A; Sun, S.C.; Karin, M. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science, 2001, 293, 1495-1499.
65. Bonizzi, G.; Bebien, M.; Otero, D.C.; Johnson-Vroom, K.E.; Cao, Y.; Vu, D.; Jegga, A.G.; Aronow, B.J; Ghosh, G.; Rickert, R.C.; Karin, M. Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J., 2004, 23, 4202-4210.
66. Bonizzi, G.; Karin, M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol, 2004, 25, 280-288.
67. Kato, T. Jr.; Delhase, M.; Hoffmann, A.; Karin, M. CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response. Mol. Cell, 2003, 12, 829-839.
68. Paulie, S.; Rosen, A.; Ehlin-Henriksson, B.; Braesch-Andersen, S.; Jakobson, E.; Koho, H.; Perlmann, P. The human B lymphocyte and carcinoma antigen, CDw40, is a phosphoprotein involved in growth signal transduction. J. Immunol, 1989, 142, 590-595.
69. Ledbetter, J.A.; Shu, G.; Gallagher, M.; Clark, E.A. Augmentation of normal and malignant B-cell proliferation by monoclonal antibody to the B-cell-specific antigen BP50 (CDW40). J. Immunol, 1987, 138, 788-794.
70. Nowak, A.K.; Robinson, B.W.; Lake, R.A. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res., 2003, 63, 4490-4496.
71. Pirozzi, G.; Lombari, V.; Zanzi, D.; Ionna, F.; Lombardi, M.L.; Errico, S.; Ruggiero, G.; Manzo, C. CD40 expressed on human melanoma cells mediates T-cell co-stimulation and tumor cell growth. Int. Immunol., 2000, 12, 787-795.
72. Ottaiano, A.; Pisano, C.; De Chiara, A.; Ascierto, P.A.; Botti, G.; Barletta, E.; Apice, G.; Gridelli, C.; Iaffaioli, V.R. CD40 activation as potential tool in malignant neoplasms. Tumori, 2002, 88, 361-366.
73. Villarroel Dorrego, M.; Whawell, S.A.; Speight, P.M.; Barrett, A.W. Transfection and ligation of CD40 in human oral keratinocytes affect proliferation, adhesion and migration but not apoptosis in vitro. Clin. Exp. Dermatol., 2006, 31, 266-271.
74. Pinzon-Charry, A.; Schmidt, C.W.; Lopez, J.A. The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction. Breast Cancer Res., 2006, 8, 402.
75. Noelle, RJ.; Erickson, LD. Determinations of B cell fate in immunity and autoimmunity. Curr. Dis. Autoimmun., 2005, 8, 1-24.
76. Koppold, B.; Sauer, G.; Buening, H.; Hallek, M.; Kreienberg, R.; Deissler, H.; Kurzeder, C. Chemotherapeutic agents enhance AAV2-mediated gene transfer into breast cancer cells promoting CD40 ligand-based immunotherapy. J. Cancer Res. Clin. Oncol., 2006, 132, 787-794.
77. Bereznaya, N.M.; Chekhun, V.F. Expression of CD40 and CD40L on tumor cells: the role of their interaction and new approach to immunotherapy. Exp. Oncol., 2007, 29, 2-12.
78. Lomaga, M.A.; Yeh, W.C.; Sarosi, I.; Duncan, G.S.; Furlonger, C.; Ho, A.; Morony, S.; Capparelli, C.; Van, G.; Kaufman, S.; van der Heiden, A.; Itie, A.; Wakeham, A.; Khoo, W.; Sasaki, T.; Cao, Z.; Penninger, J.M.; Paige, C.J.; Lacey, D.L.; Dunstan, C.R.; Boyle, W.J.; Goeddel D.V.; Mak T.W. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev., 1999, 13, 1015-1024.
79. Hauer, J.; Püschner, S.; Ramakrishnan, P.; Simon, U.; Bongers, M.; Federle, C.; Engelmann, H. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs. Proc. Natl. Acad. Sci. U S A, 2005, 102, 2874-2879.
80. Chen, H.; Li, M.; Campbell, R.A.; Burkhardt, K.; Zhu, D.; Li, S.G.; Lee, H.J.; Wang, C.; Zeng, Z.; Gordon M.S.; Bonavida, B.; Berenson, J.R. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis. Oncogene, 2006, 25, 6520-6527.
81. Liao, G.; Zhang, M.; Harhaj, E.W.; Sun, S.C. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J. Biol. Chem., 2004, 279, 26243-26250.
82. Yin, L.; Wu, L.; Wesche, H.; Arthur, C.D.; White, J.M.; Goeddel, D.V.; Schreiber, R.D. Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science, 2001, 291, 2162-2165.
83. Claudio, E.; Brown, K.; Park, S.; Wang, H.; Siebenlist, U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat. Immunol., 2002, 3, 958-965.
84. Coope, H.J.; Atkinson, P.G.; Huhse, B.; Belich, M.; Janzen, J.; Holman, M.J. CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J., 2002, 21, 5375-5385.
85. Ramakrishnan, P.; Wang, W.; Wallach, D. Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. Immunity, 2004, 21, 477-489.
86. Woronicz, J.D.; Gao, X.; Cao, Z.; Rothe, M.; Goeddel, D.V. IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science, 1997, 278, 866-869.
87. O'Mahony, A.; Lin, X.; Geleziunas, R.; Greene, W.C. Activation of the heterodimeric IkappaB kinase alpha (IKKalpha)-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions. Mol. Cell. Biol., 2000, 20, 1170-1178.
88. Brummelkamp, T.R.; Nijman, S.M.; Dirac, A.M.; Bernards, R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003, 424, 797-801.
89. Kovalenko, A.; Chable-Bessia, C.; Cantarella, G.; Israël, A.; Wallach, D.; Courtois, G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature, 2003, 424, 801-805.
90. Regamey, A.; Hohl, D.; Liu, J.W.; Roger, T.; Kogerman, P.; Toftgard, R.; Huber, M. The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor. J. Exp. Med., 2003, 198, 1959-1964.
91. Trompouki, E.; Hatzivassiliou, E.; Tsichritzis, T.; Farmer, H.; Ashworth, A.; Mosialos, G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature, 2003, 424, 793-796.
92. Massoumi, R.; Chmielarska, K.; Hennecke, K.; Pfeifer, A.; Fässler, R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell, 2006, 125, 665-677.
93. Rothe, M.; Pan, M.G.; Henzel, W.J.; Ayres, T.M.; Goeddel, D.V. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell, 1995, 83, 1243-1252.
94. Li, X.; Yang, Y.; Ashwell, J.D. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature, 2002, 416, 345-347.
95. Gerlo, S.; Haegeman, G.; Vanden Berghe, W. Transcriptional regulation of autocrine IL-6 expression in multiple myeloma cells. Cell Signal., 2008, 20, 1489-1496.
96. Chauhan, D.; Uchiyama, H.; Akbarali, Y.; Urashima, M.; Yamamoto, K.; Libermann, TA.; Anderson, KC. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood, 1996, 87, 1104-1112.
97. Pelliniemi, T.T.; Irjala, K.; Mattila, K.; Pulkki, K.; Rajamäki, A.; Tienhaara, A.; Laakso, M.; Lahtinen, R. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood, 1995, 85, 765-771.
98. Pulkki, K.; Pelliniemi, T.T.; Rajamäki, A.; Tienhaara, A.; Laakso, M.; Lahtinen, R. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group. Br. J. Haematol., 1996, 92, 370-374.
99. Fattori, E.; Della Rocca, C.; Costa, P.; Giorgio, M.; Dente, B.; Pozzi, L.; Ciliberto, G. Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. Blood 1994, 83, 2570-2579.
100. Schreck, R.; Baeuerle, P.A. NF-kappa B as inducible transcriptional activator of the granulocyte-macrophage colony-stimulating factor gene. Mol. Cell. Biol., 1990, 10, 1281-1286.
101. Zhang, X.G.; Bataille, R.; Jourdan, M.; Saeland, S.; Banchereau, J.; Mannoni, P.; Klein B. Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood, 1990, 76, 2599-2605.
102. Villunger, A.; Egle, A.; Kos, M.; Egle, D.; Tinhofer, I.; Henn, T.; Uberall, F.; Maly, K.; Greil, R. Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity. B r. J. Haematol., 1998, 102, 1069-1080.
103. Portier, M.; Zhang, X.G.; Ursule, E.; Lees, D.; Jourdan, M.; Bataille, R.; Klein, B. Cytokine gene expression in human multiple myeloma. Br. J. Haematol., 1993, 85, 514-520.
104. Novak, A.J.; Darce, J.R.; Arendt, B.K.; Harder, B.; Henderson, K.; Kindsvogel, W.; Gross J.A.; Greipp, P.R.; Jelinek, D.F. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood, 2004, 103, 689-694.
105. Tai, YT.; Li, XF.; Breitkreutz, I.; Song, W.; Neri, P.; Catley, L.; Podar, K.; Hideshima, T.; Chauhan, D.; Raje, N.; Schlossman, R.; Richardson, P.; Munshi, N.C.; Anderson K.C. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res., 2006, 66, 6675-6682.
106. Aggarwal, R.; Ghobrial, IM.; Roodman, GD. Chemokines in multiple myeloma. Exp. Hematol., 2006, 34, 1289-1295.
107. Abe, M.; Hiura, K.; Ozaki, S.; Kido, S.; Matsumoto, T. Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production. J. Bone Miner. Metab., 2009, 27, 16-23.
108. Lee, H.; Arsura, M.; Wu, M.; Duyao, M.; Buckler, A.J.; Sonenshein, G.E. Role of Rel-related factors in control of c-myc gene transcription in receptor-mediated apoptosis of the murine B cell WEHI 231 line. J. Exp. Med., 1995, 181, 1169-1177.
109. Guttridge, D.C.; Albanese, C; Reuther, J.Y.; Pestell, R.G.; Baldwin, A.S. Jr. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol, 1999, 19, 5785-5799.
110. Hinz, M.; Krappmann, D.; Eichten, A; Heder, A.; Scheidereit, C; Strauss, M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol. Cell. Biol, 1999, 19, 2690-2698.
111. Joyce, D.; Bouzahzah, B.; Fu, M.; Albanese, C; D'Amico, M.; Steer, J.; Klein, J.U.; Lee, R.J.; Segall, J.E.; Westwick, J.K.; Der, C.J.; Pestell, R.G. Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-kappaB-dependent pathway. J. Biol. Chem., 1999, 274, 25245-25249.
112. Joyce, D.; Albanese, C; Steer, J; Fu, M.; Bouzahzah, B.; Pestell, R.G. NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev., 2001, 12, 73-90.
113. Ogasawara, T.; Katagiri, M.; Yamamoto, A.; Hoshi, K.; Takato, T.; Nakamura, K.; Tanaka, S.; Okayama, H.; Kawaguchi, H. Osteoclast differentiation by RANKL requires NF-kappaB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6). J. Bone Miner. Res., 2004, 19, 1128-1136.
114. Bergsagel, PL.; Kuehl, W.M.; Zhan, F.; Sawyer, J.; Barlogie, B.; Shaughnessy, J. Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood, 2005, 106, 296-303.
115. Huang, X.; Di Liberto, M.; Jayabalan, D.; Liang, J.; Ely, S.; Bretz, J.; Shaffer A.L.; Louie, T.; Chen, I.; Randolph, S.; Hahn, W.C.; Staudt, L.M.; Niesvizky, R.; Moore, A.S.; Chen-Kiang, S. Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood, 2012, 120, 1095-1106.
116. Leone, P.E.; Walker, B.A.; Jenner, M.W.; Chiecchio, L.; Dagrada, G.; Protheroe, R.K.; Johnson, D.C.; Dickens, N.J.; Brito, J.L.; Else, M.; Gonzalez, D.; Ross, F.M.; Chen-Kiang, S.; Davies, F.E.; Morgan, G.J. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin. Cancer Res., 2008, 14, 6033-6041.
117. Ely, S.; Di Liberto, M.; Niesvizky, R.; Baughn, L.B.; Cho, H.J.; Hatada, E.N.; Knowles, D.M.; Lane, J.; Chen-Kiang, S. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res., 2005 65,11345-11353.
118. Lee, H.H.; Dadgostar, H.; Cheng, Q.; Shu, J.; Cheng, G. NF-κB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc. Natl. Acad. Sci. U S A, 1999, 96, 9136-9141.
119. Stehlik, C; de Martin, R.; Kumabashiri, I.; Schmid, J.A.; Binder, B.R.; Lipp, J. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J. Exp. Med, 1998, 188, 211-216.
120. Hu, X.; Yee, E.; Harlan, J.M.; Wong, F.; Karsan, A. Lipopolysaccharide induces the antiapoptotic molecules, A1 and A20, in microvascular endothelial cells. Blood, 1998, 92, 2759-2765.
121. Wang, C.Y; Mayo, M.W.; Korneluk, R.G.; Goeddel, D.V.; Baldwin, A.S. Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science, 1998, 281, 1680-1683.
122. Panwalkar, A.; Verstovsek, S.; Giles, F. Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies. Cancer, 2004, 100, 1578-1589.
123. Benayoun, B.; Baghdiguian, S.; Lajmanovich, A.; Bartoli, M.; Daniele, N.; Gicquel, E.; Bourg, N.; Raynaud, F.; Pasquier, M.A.; Suel, L.; Lochmuller, H.; Lefranc, G.; Richard, I. NF-kappaB-dependent expression of the antiapoptotic factor c-FLIP is regulated by calpain 3, the protein involved in limb-girdle muscular dystrophy type 2A. FASEB J., 2008, 22, 1521-1529.
124. Watanabe, M.; Dewan, M.Z.; Okamura, T.; Sasaki, M.; Itoh, K.; Higashihara, M.; Mizoguchi, H.; Honda, M.; Sata, T.; Watanabe, T.; Yamamoto, N.; Umezawa, K.; Horie, R. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int. J. Cancer, 2005, 114, 32-38.
125. Nakagawa, Y.; Abe, S.; Kurata, M.; Hasegawa, M.; Yamamoto, K.; Inoue, M.; Takemura, T.; Suzuki, K.; Kitagawa, M. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am. J. Hematol., 2006, 81, 824-831.
126. Wen, X.; Lin, Z.Q.; Liu, B.; Wei, Y.Q. Caspase-mediated programmed cell death pathways as potential therapeutic targets in cancer. Cell Prolif., 2012, 45, 217-224.
127. Rauert, H.; Stühmer, T.; Bargou, R.; Wajant, H.; Siegmund, D. TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms. Cell. Death Dis., 2011, 2, e194.
128. Akiyama, M.; Hideshima, T.; Hayashi, T.; Tai, Y.T.; Mitsiades, C.S.; Mitsiades, N.; Chauhan, D.; Richardson, P.; Munshi, N.C.; Anderson, K.C. Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res., 2003, 63, 18-21.
129. Shammas, M.A.; Koley, H.; Bertheau, R.C.; Neri, P.; Fulciniti, M.; Tassone, P.; Blotta, S.; Protopopov, A.; Mitsiades, C.; Batchu, R.B.; Anderson, K.C.; Chin, A.; Gryaznov, S.; Munshi, N.C. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia, 2008, 22, 1410-1418.
130. de la Guardia, R.D.; Catalina, P.; Panero, J.; Elosua, C.; Pulgarin, A.; López, M.B.; Ayllón, V.; Ligero, G.; Slavutsky, I.; Leone, P.E. Expression profile of telomere-associated genes in multiple myeloma. J. Cell. Mol. Med., 2012, 16, 3009-3021.
131. Kiriakidis, S.; Andreakos, E.; Monaco, C.; Foxwell, B.; Feldmann, M.; Paleolog, E. VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2. J. Cell. Sci., 2003, 116, 665-674.
132. Cramer, M.; Nagy, I.; Murphy, B.J.; Gassmann, M.; Hottiger, M.O.; Georgiev, O.; Schaffner, W. NF-kappaB contributes to transcription of placenta growth factor and interacts with metal responsive transcription factor-1 in hypoxic human cells. Biol. Chem., 2005, 386, 865-872.
133. Stifter S. The role of nuclear factor kappaB on angiogenesis regulation through monocyte chemotactic protein-1 in myeloma. Med. Hypotheses, 2006, 66, 384-386.
134. Tatsumi, T.; Shimazaki, C.; Goto, H.; Araki, S.; Sudo, Y.; Yamagata, N.; Ashihara, E.; Inaba, T.; Fujita, N.; Nakagawa, M. Expression of adhesion molecules on myeloma cells. Jpn. J. Cancer Res., 1996, 87, 837-842.
135. Sanz-Rodríguez, F.; Teixidó, J. VLA-4-dependent myeloma cell adhesion. Leuk. Lymphoma, 2001, 41, 239-245.
136. Bond, M.; Fabunmi, R.P.; Baker, A.H.; Newby, A.C. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett., 1998, 435, 29-34.
137. Vincenti, M.P.; Coon, C.I.; Brinckerhoff, C.E. Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1beta-stimulated synovial fibroblasts. Arthritis Rheum., 1998, 41, 1987-1994.
138. Hecht, M.; von Metzler, I.; Sack, K.; Kaiser, M.; Sezer, O. Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA). Exp. Cell Res., 2008, 314, 1082-1093.
139. Delaissé, J.M.; Andersen, T.L.; Engsig, M.T.; Henriksen, K.; Troen, T.; Blavier, L. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc. Res. Tech., 2003, 61, 504-513.
140. Hideshima, T.; Chauhan, D.; Richardson, P.; Mitsiades, C.; Mitsiades, N.; Hayashi, T.; Munshi, N.; Dang, L.; Castro, A.; Palombella, V.; Adams, J.; Anderson, K.C. NF-kappa B as a therapeutic target in multiple myeloma. J. Biol. Chem., 2002, 277, 16639-16647.
141. Mitsiades, N.; Mitsiades, CS.; Poulaki, V.; Chauhan, D.; Richardson, PG.; Hideshima, T.; Munshi, N.; Treon, S.P.; Anderson, K.C. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood, 2002, 99, 4079-4086.
142. Mitsiades, N.; Mitsiades, C.S.; Poulaki, V.; Chauhan, D.; Richardson, P.G.; Hideshima, T.; Munshi, N.C.; Treon, S.P.; Anderson, K.C. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 2002, 99, 4525-4530.
143. Mitsiades, C.S.; Davies, F.E.; Laubach, J.P.; Joshua, D.; San Miguel, J.; Anderson, K.C; Richardson, PG. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J. Clin. Oncol, 2011, 29, 1916-1923.
144. Chauhan, D.; Tian, Z.; Zhou, B.; Kuhn, D.; Orlowski, R.; Raje, N.; Richardson, P.; Anderson, K.C. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin. Cancer Res., 2011, 17, 5311-5321.
145. Davies, F.; Baz, R. Lenalidomide mode of action" linking bench and clinical findings. Blood Rev, 2010, 24 (Suppl.1), S13-S19.
146. Dimopoulos, M.A.; Terpos, E. Lenalidomide: an update on evidence from clinical trials. Blood Rev, 2010, 24 (Suppl.1), S21-S26.
147. Morgan, G. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies. Blood Rev, 2010, 24 (Suppl.1), S27-S32.
148. Gay, F.; Palumbo, A. Management of older patients with multiple myeloma. Blood Rev, 2011, 25, 65-73.
149. Dai, Y.; Pei, X.Y.; Rahmani, M.; Conrad, D.H.; Dent, P.; Grant, S. Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood, 2004, 103, 2761-2770.
150. Hideshima, T.; Neri, P.; Tassone, P.; Yasui, H.; Ishitsuka, K.; Raje, N.; Chauhan, D.; Podar, K.; Mitsiades, C; Dang, L.; Munshi, N.; Richardson, P.; Schenkein, D.; Anderson, K.C. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin. Cancer Res., 2006, 12, 5887-5894.
151. Romagnoli, M.; Desplanques, G.; Maïga, S.; Legouill, S.; Dreano, M.; Bataille, R.; Barillé-Nion, S. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. Clin. Cancer Res., 2007, 13, 6010-6018.
152. Jourdan, M.; Moreaux, J.; Vos, JD.; Hose, D.; Mahtouk, K.; Abouladze, M.; Robert, N.; Baudard, M.; Rème, T.; Romanelli, A.; Goldschmidt, H.; Rossi, J.F.; Dreano, M.; Klein, B. Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth. Br. J. Haematol, 2007, 138, 160-168.
153. Malara, N.; Focà, D.; Casadonte, F.; Sesto, MF.; Macrina, L.; Santoro, L.; Scaramuzzino, M.; Terracciano, R.; Savino, R. Simultaneous inhibition of the constitutively activated nuclear factor kappaB and of the interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells. Cell Cycle, 2008, 7, 3235-3245.
154. Hideshima, T; Anderson, K.C. Biologic impact of proteasome inhibition in multiple myeloma cells-from the aspects of preclinical studies. Semin. Hematol, 2012, 49, 223-227.
155. Kapoor, P.; Ramakrishnan, V.; Rajkumar, S.V. Bortezomib combination therapy in multiple myeloma. Semin. Hematol, 2012, 49, 228-242.
156. Markovina, S.; Callander, N.S.; O'Connor S.L., Kim J.; Werndli, J.E.; Raschko, M.; Leith, C.P.; Kahl, B.S.; Kim, K.; Miyamoto, S. Bortezomib-resistant nuclear factor-KB activity in myeloma cells. Mol. Cancer Res., 2008, 6, 1356-1364.
157. Markovina, S.; Callander, N.S.; O'Connor, S.L.; Xu, G.; Shi, Y; Leith, C.P; Kim, K.; Trivedi, P.; Kim, J.; Hematti, P.; Miyamoto, S. Bone marrow stromal cells from multiple myeloma paytients uniquely induce bortezomib resistant NF-κB activity in myeloma cells. Mol. Cancer, 2010, 9, 176.
158. Balsas, P.; Galán-Malo, P.; Marzo, I.; Naval, J. Bortezomib resistance in a myeloma cell line is associated to PSMp5 overexpression and polyploidy. Leuk. Res. 2012, 363, 212-218.
159. Richardson, P.G.; Chanan-Khan, A.A.; Lonial, S.; Krishnan, A.Y; Carroll, M.P; Alsina, M.; Albitar, M.; Berman, D.; Messina, M.; Anderson, K.C. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br. J. Haematol, 2011, 153, 729-740.
160. Demo, S.D.; Kirk, C.J.; Aujay, M.A.; Buchholz, T.J.; Dajee, M.; Ho, M.N.; Jiang, J.; Laidig, G.J.; Lewis, E.R.; Parlati, F.; Shenk, K.D.; Smyth, M.S.; Sun, CM.; Vallone, M.K.; Woo, T.M.; Molineaux, C.J.; Bennett, M.K. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res., 2007, 67, 6383-6391.
161. Vij, R.; Siegel, D.S.; Jagannath, S.; Jakubowiak, A.J.; Stewart, A.K.; McDonagh, K.; Bahlis, N.; Belch, A.; Kunkel, L.A.; Wear, S.; Wong, A.F.; Wang, M. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br. J. Haematol, 2012, 158, 739-748.
162. Hajek, R.; Bryce, R.; Ro, S.; Klencke, B.; Ludwig, H. Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM). BMC Cancer., 2012, 12, 415.
163. Fuchs, O.; Provaznikova, D.; Marinov, I.; Kuzelova, K.; Spicka, I. Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells. Cardiovasc. Hematol Disord. Drug Targets., 2009, 9, 62-77.
164. Khan, R.Z.; Badros, A. Role of carfilzomib in the treatment of multiple myeloma. Expert. Rev. Hematol, 2012, 5, 361-372.
165. Jakubowiak, A.J.; Dytfeld, D.; Griffith, K.A.; Lebovic, D.; Vesole, D.H.; Jagannath, S.; Al-Zoubi, A.; Anderson, T.; Nordgren, B.; Detweiler-Short, K.; Stockerl-Goldstein, K.; Ahmed, A.; Jobkar, T.; Durecki, D.E.; McDonnell, K.; Mietzel, M.; Couriel, D.; Kaminski, M.; Vij, R. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood, 2012, 120, 1801-1809.
166. Zhou, H.J.; Aujay, M.A.; Bennett, M.K.; Dajee, M.; Demo, S.D.; Fang, Y.; Ho, M.N.; Jiang, J.; Kirk, C.J.; Laidig, G.J.; Lewis, E.R.; Lu, Y.; Muchamuel, T.; Parlati, F; Ring, E.; Shenk, K.D.; Shields, J.; Shwonek, P.J.; Stanton, T.; Sun, CM.; Sylvain, C; Woo T.M.; Yang, J. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J. Med. Chem., 2009, 52, 3028-3038.
167. Meinel, F.G.; Mandl-Weber, S.; Baumann, P.; Leban, J.; Schmidmaier, R. The novel, proteasome-independent NF-kappaB inhibitor V1810 induces apoptosis and cell cycle arrest in multiple myeloma and overcomes NF-kappaB-mediated drug resistance. Mol Cancer Ther, 2010, 9, 300-310.
168. Fabre, C; Mimura, N.; Bobb, K.; Kong, S.Y; Gorgun, G.; Cirstea, D.; Hu, Y; Minami, J.; Ohguchi, H.; Zhang, J.; Meshulam, J.; Carrasco, R.D.; Tai, Y.T.; Richardson, P.G.; Hideshima, T.; Anderson, K.C. Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma. Clin. Cancer Res., 2012, 18, 4669-4681.
169. Palumbo, A.; Hajek, R.; Delforge, M.; Kropff, M.; Petrucci, M.T.; Catalano, J.; Gisslinger, H.; Wiktor-Jedrzejczak, W.; Zodelava, M.; Weisel, K.; Cascavilla, N.; Iosava, G; Cavo, M.; Kloczko, J.; Bladé, J.; Beksac, M.; Spicka, I.; Plesner, T.; Radke, J.; Langer, C; Ben Yehuda, D.; Corso, A.; Herbein, L.; Yu, Z.; Mei, J.; Jacques, C; Dimopoulos, M.A.; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N. Engl. J. Med., 2012, 366, 1759-1769.
170. McCarthy, PL.; Owzar, K.; Hofmeister, C.C.; Hurd, D.D.; Hassoun, H.; Richardson, P.G.; Giralt, S.; Stadtmauer, E.A.; Weisdorf, D.J.; Vij, R.; Moreb, J.S.; Callander, N.S.; Van Besien, K.; Gentile, T.; Isola, L.; Maziarz, R.T.; Gabriel, D.A.; Bashey, A.; Landau, H.; Martin, T.; Qazilbash, M.H.; Levitan, D.; McClune, B.; Schlossman, R.; Hars, V; Postiglione, J.; Jiang, C; Bennett, E.; Barry, S.; Bressler, L.; Kelly, M.; Seiler, M.; Rosenbaum, C; Hari, P.; Pasquini, M.C.; Horowitz, M.M.; Shea, T.C.; Devine, S.M.; Anderson, K.C; Linker, C. Lenalidomide after stem-cell transplantation for multiple myeloma. N. Engl. J. Med., 2012, 366, 1770-1781.
171. Attal, M.; Lauwers-Cances, V; Marit, G.; Caillot, D.; Moreau, P.; Facon, T.; Stoppa, A.M.; Hulin, C; Benboubker, L.; Garderet, L.; Decaux, O.; Leyvraz, S.; Vekemans, M.C.; Voillat, L.; Michallet, M.; Pegourie, B.; Dumontet, C.; Roussel, M.; Leleu, X.; Mathiot, C.; Payen, C.; Avet-Loiseau, H.; Harousseau, J.L.; IFM Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N. Engl. J. Med., 2012, 366, 1782-1791.
172. Sedlarikova, L.; Kubiczkova, L.; Sevcikova, S.; Hajek, R. Mechanism of immunomodulatory drugs in multiple myeloma. Leuk. Res., 2012, 36, 1218-1224.
173. Zhu, Y.X.; Kortuem, K.M.; Stewart, A.K. Molecular mechanism of action of the immune-modulatory drugs, thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk. Lymphoma, 2012, (doi:10.3109/10428194.2012.728597)
174. Keifer, J.A.; Guttridge, D.C.; Ashburner, B.P.; Baldwin, A.S. Jr.; Keifer, J.A.; Guttridge, D.C.; Ashburner, B.P.; Baldwin, A.S. Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J. Biol. Chem., 2001, 276, 22382-22387.
175. De Luisi, A.; Ferrucci, A.; Coluccia, A.M.; Ria, R.; Moschetta, M.; de Luca, E.; Pieroni, L.; Maffia, M.; Urbani, A.; Di Pietro, G.; Guarini, A.; Ranieri, G.; Ditonno, P.; Berardi, S.; Caivano, A.; Basile, A.; Cascavilla, N.; Capalbo, S.; Quarta, G.; Dammacco, F.; Ribatti, D.; Vacca, A. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin. Cancer Res., 2011, 17, 1935-1946.
176. Ito, T.; Ando, H.; Suzuki, T.; Ogura, T.; Hotta, K.; Imamura, Y.; Yamaguchi, Y.; Handa, H. Identification of a primary target of thalidomide teratogenicity. Science, 2010, 327, 1345-1350.
177. Lopez-Girona, A.; Heintel, D.; Zhang, L.H.; Mendy, D.; Gaidarova, S.; Brady, H.; Bartlett, J.B.; Schafer, P.H.; Schreder, M.; Bolomsky, A.; Hilgarth, B.; Zojer, N.; Gisslinger, H.; Ludwig, H.; Daniel, T.; Jäger, U.; Chopra, R. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br. J. Haematol., 2011, 154, 325-336.
178. Zhu, Y.X.; Braggio, E.; Shi, C.X.; Bruins, L.A.; Schmidt, J.E.; Van Wier, S.; Chang, X.B.; Bjorklund, C.C.; Fonseca, R.; Bergsagel, P.L.; Orlowski, R.Z.; Stewart, A.K. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood, 2011, 118, 4771-4779.
179. A.; Mendy D.; Ito, T.; Miller K, Gandhi, A.K.; Kang J, Karasawa, S.; Carmel G.; Jackson P, Abbasian M, Mahmoudi, A.; Cathers, B.; Rychak, E.; Gaidarova, S.; Chen, R.; Schafer, P.H.; Handa, H.; Daniel, T.O.; Evans, J.F.; Chopra, R. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia, 2012, 26, 2326-2335.
180. YinJun, L.; Jie, J.; YunGui, W. Triptolide inhibits transcription factor NF-kappaB and induces apoptosis of multiple myeloma cells. Leuk. Res., 2005, 29, 99-105.
181. Wang, X.; Matta R.; Shen, G.; Nelin, L.D.; Pei, D.; Liu, Y. Mechanism of triptolide-induced apoptosis: Effect on caspase activation and Bid cleavage and essentiality of the hydroxyl group of triptolide. J. Mol. Med., 2006, 84, 405-415.
182. Bao, X.; Cui, J.; Wu, Y.; Han, X.; Gao, C.; Hua, Z.; Shen, P. The roles of endogenous reactive oxygen species and nitric oxide in triptolide-induced apoptotic cell death in macrophages. J. Mol. Med., 2007, 85, 85-98.
183. Tiedemann, R.E.; Schmidt, J.; Keats, J.J.; Shi, CX.; Zhu, Y.X.; Palmer, S.E.; Mao, X.; Schimmer, A.D.; Stewart, A.K. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with anti-myeloma activity in vitro and in vivo. Blood, 2009, 113, 4027-4037.
184. Boyd, E.M.; Bench, A.J.; van't Veer M.B, Wright, P.; Bloxham, D.M.; Follows, G.A. Scott, M.A. High resolution meling analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies. Br. J. Haematol., 2011, 155, 609-612.
185. Ribas, A.; Flaherty, K.T. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat. Rev. Clin. Oncol., 2011, 8, 426-433.
186. van Haaften, G.; Dalgliesh, G.L.; Davies, H.; Chen, L.; Bignell, G.; Greenman, C.; Edkins, S.; Hardy, C.; O'Meara, S.; Teague, J.; Butler, A.; Hinton, J.; Latimer, C.; Andrews, J.; Barthorpe, S.; Beare, D.; Buck, G.; Campbell, P.J.; Cole, J.; Forbes, S.; Jia, M.; Jones, D.; Kok, C.Y.; Leroy, C; Lin, M.L.; McBride, D.J.; Maddison, M.; Maquire, S.; McLay, K.; Menzies, A.; Mironenko, T.; Mulderrig, L.; Mudie, L.; Pleasance, E.; Shepherd, R.; Smith, R.; Stebbings, L.; Stephens, P.; Tang, G.; Tarpey, P.S.; Turner, R.; Turrell, K.; Varian, J.; West, S.; Widaa, S.; Wray, P.; Collins, V.P; Ichimura, K.; Law, S.; Wong, J.; Yuen, S.T.; Leung, S.Y.; Tonon, G.; DePinho, R.A.; Tai, Y.T.; Anderson, K.C.; Kahnoski, R.J.; Massie, A.; Khoo, S.K.; The, B.T.; Stratton, M.R.; Futreal, PA. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet., 2009, 41, 521-523.
187. Smith, E.M.; Boyd, K.; Davies, F.E. The potential role of epigenetic therapy in multiple myeloma. Br. J. Haematol, 2010, 148, 702-713.
188. Jugová, A.; Sustácková, G.; Legartová, S.; Stixová, L.; Kozubek, S.; Bártová, E. Effects of epigenetic-based anti-cancer drugs in leukaemia and multiple myeloma cells. Cell. Biol. Int., 2011, 35, 1195-1203.
189. Niesvizky, R.; Ely, S.; Mark, T.; Aggarwal, S.; Gabrilove, J.L.; Wright, J.J.; Chen-Kiang, S.; Sparano, J.A. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer, 2011, 117, 336-342.
190. Heller, G.; Schmidt, W.M.; Ziegler, B.; Holzer, S.; Müllauer, L.; Bilban, M.; Zielinski, C.C.; Drach, J.; Zöchbauer-Müller, S. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res., 2008, 68, 44-54.
191. Chauhan, D.; Bandi, M.; Singh, A.V.; Ray, A.; Raje, N.; Richardson, P.; Anderson, K.C. Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells. Br. J. Haematol, 2011, 155, 588-598.
192. Min, D.J.; Ezponda, T; Kim, M.; Will, CM.; Martinez-Garcia, E.; Popovic, R.; Basrur, V.; Elenitoba-Johnson, K.S.; Licht, J.D. MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC. Leukemia, 2012, (doi 10.1038/leu.2012.269).
193. Martinez-Garcia, E.; Popovic, R.; Min, D.J.; Sweet, S.M.; Thomas, P.M.; Zamdborg, L.; Heffner, A.; Will, C; Lamy, L.; Staudt, L.M.; Levens, D.L.; Kelleher, N.L.; Licht, J.D. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood, 2011, 117, 211-220.
194. Bolden, J.E.; Peart, M.J.; Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov., 2006, 5, 769-784.
195. Richardson, P.; Mitsiades, C; Colson, K.; Reilly, E.; McBride, L.; Chiao, J.; Sun, L.; Ricker, J.; Rizvi, S.; Oerth, C; Atkins, B.; Fearen, I.; Anderson, K.; Siegel, D. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk. Lymphoma, 2008, 49, 502-507.
196. McMillin, D.W.; Ooi, M.; Delmore, J.; Negri, J.; Hayden, P.; Mitsiades, N.; Jakubikova, J.; Maira, S.M.; Garcia-Echeverria, C; Schlossman, R.; Munshi, N.C.; Richardson, P.G.; Anderson, K.C; Mitsiades, C.S. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res., 2009, 69, 5835-5842.
197. Baumann, P.; Mandl-Weber, S.; Oduncu, F.; Schmidmaier, R. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp. Cell Res., 2009, 315, 485-497.
198. Baumann, P.; Schneider, L.; Mandl-Weber, S.; Oduncu, F.; Schmidmaier, R. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs, 2012, 23, 131-138.
199. Roberts, P.J.; Der, C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 2007, 26, 3291-3310.
200. Chng, W.J.; Gonzalez-Paz, N.; Price-Troska, T; Jacobus, S.; Rajkumar, S.V.; Oken, M.M.; Kyle, R.A.; Henderson, K.J.; Van Wier, S.; Greipp, P.; Van Ness, B.; Fonseca, R. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia, 2008, 22, 2280-2284.
201. Reuter, C.W.M.; Morgan, M.A.; Bergmann, L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematological malignancies? Blood, 2000, 96, 1655-1669.
202. Alsina, M.; Fonseca, R.; Wilson, E.F.; Belle, A.N.; Gerbino, E.; Price-Troska, T.; Overton, R.M.; Ahmann, G.; Bruzek, L.M.; Adjei, A.A.; Kaufmann, S.H.; Wright, J.J.; Sullivan, D.; Djulbegovic, B.; Cantor, A.B.; Greipp, P.R.; Dalton, W.S.; Sebti, S.M. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood, 2004, 103, 3271-3277.
203. David, E.; Kaufman, J.L.; Flowers, C.R.; Schafer-Hales, K.; Torre, C.; Chen, J.; Marcus, A.I.; Sun, S.Y.; Boise, L.H.; Lonial, S. Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Blood, 2010, 116, 5285-5288.
204. Ramakrishnan, V.; Timm, M.; Haug, J.L.; Kimlinger, T.K.; Wellik, L.E.; Witzig, T.E.; Rajkumar, S.V.; Adjei, A.A.; Kumar, S. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene, 2010, 29, 1190-1202.
205. Kharaziha, P.; De Raeve, H.; Fristedt, C.; Li, Q.; Gruber, A.; Johnsson, P.; Kokaraki, G.; Panzar, M.; Laane, E.; Osterborg, A.; Zhivotovsky, B.; Jernberg-Wiklund, H.; Grander, D.; Celsing, F.; Bjorkholm, M.; Vanderkerken, K.; Panaretakis, T. Sorafenib has potent anti-tumor activity in multiple myeloma in vitro, ex vivo and in vivo, in the 5T33MM mouse model. Cancer Res. 2012, 72, 5348-5362.
206. David, E.; Sun, S.Y.; Waller, E.K.; Chen, J.; Khuri, F.R.; Lonial, S. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood, 2005, 106, 4322-4329.
207. Amit-Vazina, M.; Shishodia, S.; Harris, D.; Van, Q.; Wang, M.; Weber, D.; Alexanian, R.; Talpaz, M.; Aggarwal, B.B.; Estrov, Z. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br. J. Cancer, 2005, 93, 70-80.
208. Ramakrishnan, V.; Kimlinger, T.; Haug, J.; Timm, M.; Wellik, L.; Halling, T.; Pardanani, A.; Tefferi, A.; Rajkumar, S.V.; Kumar, S. TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. Am. J. Hematol., 2010, 85, 675-686.
209. Sansone, P.; Bromberg, J. Targeting the interleukin-6/Jak/Stat pathway in human malignancies. J. Clin. Oncol., 2012, 30, 1005-1014.
210. Myeloma TrialistśCollaborative Group: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials: Myeloma TrialistśCollaborative Group. J. Clin. Oncol., 1998, 16, 3832-3842.
211. Attal, M.; Harousseau, J.L. Standard therapy versus autologous transplantation in multiple myeloma. Hematol. Oncol. Clin. North Am., 1997, 11, 133-146.
212. Stewart, A.K.; Richardson, P.G.; San-Miguel, J.F. How I treat multiple myeloma in younger patients. Blood, 2009, 114, 5436-5443.
213. Cavo, M.; Pantani, L.; Petrucci, M.T.; Patriarca, F.; Zamagni, E.; Donnarumma, D.; Crippa, C.; Boccadoro, M.; Perrone, G.; Falcone, A.; Nozzoli, C.; Zambello, R.; Masini, L.; Furlan, A.; Brioli, A.; Derudas, D.; Ballanti, S.; Dessanti, M.L.; De Stefano, V.; Carella, A.M.; Marcatti, M.; Nozza, A.; Ferrara, F.; Callea, V.; Califano, C.; Pezzi, A.; Baraldi, A.; Grasso, M.; Musto, P.; Palumbo, A.; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood, 2012, 120, 9-19.
214. Lonial, S.; Kaufman, J.L. The era of combination therapy in myeloma. J. Clin. Oncol., 2012, 30, 2434-2436.
215. Garderet, L.; Iacobelli, S.; Moreau, P.; Dib, M.; Lafon, I.; Niederwieser, D.; Masszi, T.; Fontan, J.; Michallet, M.; Gratwohl, A.; Milone, G.; Doyen, C.; Pegourie, B.; Hajek, R.; Casassus, P.; Kolb, B.; Chaleteix, C.; Hertenstein, B.; Onida, F.; Ludwig, H.; Ketterer, N.; Koenecke, C.; van Os, M.; Mohty, M.; Cakana, A.; Gorin, N.C.; de Witte, T.; Harousseau, J.L.; Morris, C.; Gahrton, G. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol., 2012, 30, 2475-2482.
216. Reece, D.E. Carfilzomib in multiple myeloma: gold, silver or bronze? Blood, 2012, 120, 2776-2777.
217. Siegel, D.S.; Martin, T.; Wang, M.; Vij, R.; Jakubowiak, A.J.; Lonial, S.; Trudel, S.; Kukreti, V.; Bahlis, N.; Alsina, M.; Chanan-Khan, A.; Buadi, F.; Reu, F.J.; Somio, G.; Zonder, J.; Song, K.; Stewart, A.K.; Stadtmauer, E.; Kunkel, L.; Wear, S.; Wong, A.F.; Orlowski, R.Z., Jaganath, S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood, 2012, 120, 2817-2825.
218. Soysa, N.S.; Alles, N. NF-kappaB functions in osteoclasts. Biochem. Biophys. Res. Commun., 2009, 378, 1-5.
219. Saha, M.N.; Jiang, H.; Mukai, A.; Chang, H. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses. Mol. Cancer Ther., 2010, 9, 3041-3051.
220. Pichiorri, F.; Suh, S.S.; Rocci, A.; De Luca, L.; Taccioli, C.; Santhanam, R.; Zhou, W.; Benson, D.M. Jr.; Hofmainster, C.; Alder, H.; Garofalo, M.; Di Leva, G.; Volinia, S.; Lin, H.J.; Perrotti, D.; Kuehl, M.; Aqeilan, R.I.; Palumbo, A.; Croce, C.M. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell, 2010, 18, 367-381.
221. Corthals, S.L.; Sun, S.M.; Kuiper, R.; de Knegt, Y.; Broyl, A.; van der Holt, B.; Beverloo, H.B.; Peeters, J.K.; El Jarari, L.; Lokhorst, H.M.; Zweegman, S.; Jongen-Lavrencic, M.; Sonneveld, P. MicroRNA signatures characterize multiple myeloma patients. Leukemia, 2011, 25, 1784-1789.